Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9348292 | 0.87 | PIM1 (0.49) | GRM5NPC1RAB9APDE10ADHODH | |
| SCHEMBL1761109 | 0.84 | MAPT (0.47) | GRM5NPC1RAB9APKMCYP1A2 | |
| SCHEMBL2160345 | 0.83 | PDE10A (0.50) | PDE10A | |
| SCHEMBL4134330 | 0.83 | PRKCI (0.52) | NPC1RAB9APKMNAMPTL3MBTL1 | |
| SCHEMBL7451249 | 0.82 | PDE10A (0.60) | PDE10A | |
| SCHEMBL12595506 | 0.80 | NPC1 (0.54) | GRM5NPC1RAB9APDE10ANAMPT | |
| SCHEMBL4908197 | 0.80 | GRM5 (0.68) | GRM5NPC1RAB9APDE10APKM | |
| Hydrochloric Acid SCHEMBL1386045 | 0.79 | NPC1 (0.53) | GRM5NPC1RAB9APDE10ANAMPT | |
| Hydrochloric Acid SCHEMBL1761107 | 0.78 | GRM5 (0.66) | GRM5PDE10A | |
| SCHEMBL12595512 | 0.78 | PDE10A (0.52) | GRM5NPC1RAB9APDE10ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858862-B1 | PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | claimed |
| CN-101208311-B | Pyrazine -2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE | 2013-06-12 | — | — | CN | claimed |
| US-20090233944-A1 | PYRAZINE-2-CARBOXYAMIDE DERIVATIVES | JAESCHKE GEORG | 2009-09-17 | — | — | US | claimed |
| CN-101208311-A | Pyrazine -2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | claimed |
| EP-1858862-A1 | PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-11-28 | — | — | EP | claimed |
| WO-2006094691-A1 | PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | claimed |
| US-20060199828-A1 | Pyrazine-2-carboxyamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-07 | — | — | US | claimed |
| EP-1858862-B1 | PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| CN-101208311-B | Pyrazine -2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE | 2013-06-12 | — | — | CN | disclosed |
| US-20090233944-A1 | PYRAZINE-2-CARBOXYAMIDE DERIVATIVES | JAESCHKE GEORG | 2009-09-17 | — | — | US | disclosed |
| CN-101208311-A | Pyrazine -2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | disclosed |
| EP-1858862-A1 | PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094691-A1 | PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199828-A1 | Pyrazine-2-carboxyamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233944-A1 | PYRAZINE-2-CARBOXYAMIDE DERIVATIVES | CNR2, CNR1, CHRNA2 | GRM5 99/4885NPC1 2019/4885RAB9A 2540/4885 |
| US-20060199828-A1 | Pyrazine-2-carboxyamide derivatives | CNR2, CNR1, CHRNA2 | GRM5 99/4885NPC1 2019/4885RAB9A 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.